In this context, NSCLC with an inflamed profile is considered the optimal target for anti‐PD‐1/PD‐L1 treatment, and PD‐L1 expression on tumor cells is considered an important marker, despite it being difficult to precisely assign patients to these three theoretical profiles. The gene discussed is CD274; the disease is neoplasm.